ZIVO Bioscience (ZIVO) Competitors $18.00 0.00 (0.00%) As of 05/15/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsTrendsBuy This Stock ZIVO vs. SOPH, ESPR, ALMS, PRME, CRGX, ANNX, HUMA, TVGN, ACTU, and VYGRShould you be buying ZIVO Bioscience stock or one of its competitors? The main competitors of ZIVO Bioscience include SOPHiA GENETICS (SOPH), Esperion Therapeutics (ESPR), Alumis (ALMS), Prime Medicine (PRME), CARGO Therapeutics (CRGX), Annexon (ANNX), Humacyte (HUMA), Tevogen Bio (TVGN), Actuate Therapeutics (ACTU), and Voyager Therapeutics (VYGR). These companies are all part of the "pharmaceutical products" industry. ZIVO Bioscience vs. SOPHiA GENETICS Esperion Therapeutics Alumis Prime Medicine CARGO Therapeutics Annexon Humacyte Tevogen Bio Actuate Therapeutics Voyager Therapeutics SOPHiA GENETICS (NASDAQ:SOPH) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, valuation, institutional ownership, earnings, community ranking, media sentiment, dividends, profitability and analyst recommendations. Is SOPH or ZIVO more profitable? ZIVO Bioscience has a net margin of 0.00% compared to SOPHiA GENETICS's net margin of -110.71%. ZIVO Bioscience's return on equity of 0.00% beat SOPHiA GENETICS's return on equity.Company Net Margins Return on Equity Return on Assets SOPHiA GENETICS-110.71% -55.06% -38.33% ZIVO Bioscience N/A N/A -2,240.92% Do insiders and institutionals have more ownership in SOPH or ZIVO? 31.6% of SOPHiA GENETICS shares are owned by institutional investors. Comparatively, 12.8% of ZIVO Bioscience shares are owned by institutional investors. 4.9% of SOPHiA GENETICS shares are owned by company insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has better earnings and valuation, SOPH or ZIVO? ZIVO Bioscience has lower revenue, but higher earnings than SOPHiA GENETICS. ZIVO Bioscience is trading at a lower price-to-earnings ratio than SOPHiA GENETICS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSOPHiA GENETICS$67.17M2.94-$78.98M-$1.00-2.96ZIVO Bioscience$15.85K4,330.22-$7.78M-$4.28-4.21 Do analysts prefer SOPH or ZIVO? SOPHiA GENETICS currently has a consensus price target of $6.80, suggesting a potential upside of 129.73%. Given SOPHiA GENETICS's stronger consensus rating and higher possible upside, equities analysts clearly believe SOPHiA GENETICS is more favorable than ZIVO Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SOPHiA GENETICS 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75ZIVO Bioscience 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in SOPH or ZIVO? ZIVO Bioscience received 80 more outperform votes than SOPHiA GENETICS when rated by MarketBeat users. However, 70.37% of users gave SOPHiA GENETICS an outperform vote while only 60.74% of users gave ZIVO Bioscience an outperform vote. CompanyUnderperformOutperformSOPHiA GENETICSOutperform Votes1970.37% Underperform Votes829.63% ZIVO BioscienceOutperform Votes9960.74% Underperform Votes6439.26% Does the media refer more to SOPH or ZIVO? In the previous week, SOPHiA GENETICS had 5 more articles in the media than ZIVO Bioscience. MarketBeat recorded 5 mentions for SOPHiA GENETICS and 0 mentions for ZIVO Bioscience. ZIVO Bioscience's average media sentiment score of 1.05 beat SOPHiA GENETICS's score of 0.50 indicating that ZIVO Bioscience is being referred to more favorably in the news media. Company Overall Sentiment SOPHiA GENETICS Neutral ZIVO Bioscience Positive Which has more risk and volatility, SOPH or ZIVO? SOPHiA GENETICS has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of 0.03, meaning that its stock price is 97% less volatile than the S&P 500. SummarySOPHiA GENETICS beats ZIVO Bioscience on 11 of the 18 factors compared between the two stocks. Get ZIVO Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for ZIVO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZIVO vs. The Competition Export to ExcelMetricZIVO BioscienceBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$68.63M$2.88B$5.35B$8.51BDividend YieldN/A1.92%4.95%4.13%P/E Ratio-3.6930.1726.8519.95Price / Sales4,330.22405.60389.68119.17Price / CashN/A168.6838.2534.62Price / Book-22.223.066.764.59Net Income-$7.78M-$72.17M$3.23B$248.34M7 Day Performance12.78%3.84%4.41%5.01%1 Month Performance20.08%10.43%11.06%14.61%1 Year Performance125.56%-29.64%14.70%6.88% ZIVO Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZIVOZIVO BioscienceN/A$18.00flatN/A+125.6%$68.63M$15,850.00-3.6910News CoveragePositive NewsSOPHSOPHiA GENETICS2.39 of 5 stars$3.14+3.6%$6.80+116.6%-33.0%$209.40M$65.17M-2.88520ESPREsperion Therapeutics3.5935 of 5 stars$1.05-3.7%$6.42+511.1%-66.2%$208.06M$332.31M-1.64200Gap UpALMSAlumis2.2899 of 5 stars$4.40-4.1%$25.86+487.7%N/A$207.78MN/A0.00N/ANews CoverageEarnings ReportAnalyst ForecastHigh Trading VolumePRMEPrime Medicine2.844 of 5 stars$1.57-6.5%$13.38+751.9%-81.4%$205.92M$2.98M-0.77234Analyst RevisionCRGXCARGO Therapeutics1.9154 of 5 stars$4.23-2.1%$15.00+254.6%-81.0%$199.20MN/A-0.99116Positive NewsANNXAnnexon1.7913 of 5 stars$1.81-8.1%$18.67+931.3%-59.8%$198.58MN/A-1.7260News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHUMAHumacyte2.345 of 5 stars$1.26-3.8%$13.71+988.4%-70.8%$195.45M$1.57M-0.94150Earnings ReportAnalyst ForecastAnalyst RevisionTVGNTevogen Bio3.166 of 5 stars$1.06+5.0%$7.10+569.8%+18.6%$194.93MN/A0.003ACTUActuate TherapeuticsN/A$9.89-6.1%$20.50+107.3%N/A$193.17MN/A0.0010Earnings ReportVYGRVoyager Therapeutics4.6353 of 5 stars$3.49-4.1%$13.97+300.2%-61.7%$193.04M$80.00M4.92100News Coverage Related Companies and Tools Related Companies SOPH Alternatives ESPR Alternatives ALMS Alternatives PRME Alternatives CRGX Alternatives ANNX Alternatives HUMA Alternatives TVGN Alternatives ACTU Alternatives VYGR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZIVO) was last updated on 5/16/2025 by MarketBeat.com Staff From Our PartnersWashington Is Broke—and Eyeing Your Savings NextWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowMusk has launched a bold new AI initiative—and while you can’t invest in it directly, one overlooked stock cou...Behind the Markets | Sponsored🚨 Nvidia Just Inked a $7B AI Deal—This Could Change EverythingOn Wednesday, Nvidia stock surged—again. Why? Because Saudi Arabia just announced a multi-billion-dollar AI...Timothy Sykes | SponsoredA New Wealth Divide Is Forming NowOver the years, my proprietary stock system has identified some of the biggest winners long before Wall Street...InvestorPlace | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored How much money will YOU make when gold hits $5,000?What if I told you there was a way to secure a shot at making asymmetric gains from gold’s current historic bu...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIVO Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ZIVO Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZIVO Stock Free ZIVO Stock Alerts